AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.

Trial Details

NCT ID
NCT05404906
Phase
PHASE2 / PHASE3
Sponsor
The First Affiliated Hospital of Soochow University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Azacitidine
  • Venetoclax
  • Supportive care
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Diagnosis of favorable-risk acute myeloid leukemia (AML) according to revised 2017 European LeukemiaNet genetic risk stratification and are not imme…
  • Aged 18-64 years.
  • Patients who have received remission induction therapy and 3-4 HiDAC or medium-dose cytarabine-based consolidation and are in their first remission.
  • ECOG performance status of \< or = 3.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →